[
    {
        "id": "osp-2625",
        "type": "article-journal",
        "title": "Steroid-induced Strongyloidiasis with Cholestasis Post-COVID-19 Pneumonia",
        "author": [
            {
                "family": "Al Busaidi",
                "given": "Noora"
            },
            {
                "family": "Al Farsi",
                "given": "Fatma"
            },
            {
                "family": "Al Batashi",
                "given": "Huda"
            },
            {
                "family": "Kashoub",
                "given": "Masoud Salim"
            },
            {
                "family": "Al Sinani",
                "given": "Ahmed"
            },
            {
                "family": "Al Balushi",
                "given": "Zakariya"
            },
            {
                "family": "Khamis",
                "given": "Faryal"
            }
        ],
        "URL": "https://omanscience.com/en/articles/steroid-induced-strongyloidiasis-with-cholestasis-post-covid-19-pneumonia",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2023
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2023.31",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "The use of immunosuppressive agents has recently been raised during the COVID-19 pandemic to manage the COVID-19-induced systemic inflammatory response and improve mortality. This widespread use of steroids and other immunomodulators for severe COVID-19 diseases might pose a potential risk of reactivation of latent diseases and the emergence of opportunistic infections such as strongyloidiasis. We report a case of strongyloidiasis with cholestasis in a middle-aged man; who was otherwise healthy and had no history of recent travel, developed three weeks after a prolonged course of steroids for the management of severe COVID-19 pneumonia. The patient was managed with a combination of albendazole and ivermectin. A high index of suspicion of strongyloidiasis in symptomatic patients post immunosuppressant therapy for severe COVID-19 is required to prevent unfavorable outcomes. In selected high-risk patients, post prolonged steroid therapy for COVID-19 pneumonia screening for strongyloidiasis and ivermectin empirical treatment might be considered even in non-endemic areas."
    }
]